Section Arrow
AGMB.NASDAQ
- Agomab Therapeutics NV
Quotes are at least 15-min delayed:2026/08/12 08:40 EDT
Pre Market
Last
 --
-- (--)
Bid
--
Ask
15.5
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 14.85
-0.15 (-1.00%)
Day High 
15.5 
Prev. Close
15 
1-M High
15.4437 
Volume 
60.99K 
Bid
--
Ask
15.5
Day Low
14.53 
Open
15.1 
1-M Low
11.215 
Market Cap 
738.72M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.61 
20-SMA 12.92 
50-SMA 12.29 
52-W High 17.82 
52-W Low 8.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.35/-1.99
Enterprise Value
739.72M
Balance Sheet
Book Value Per Share
6.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.3055+0.0331+12.15%-- 
Pre Market 0.2856 -0.0199 -6.51%
TENXTenax Therapeutics1.62+0.245+17.82%-- 
Pre Market 1.6203 +0.0003 +0.02%
PDSBPDS Biotechnology Corp0.2568-0.4743-64.87%-- 
Pre Market 0.2677 +0.0109 +4.24%
DRMADermata Therapeutics Inc1.08-0.04-3.57%-- 
Pre Market 1.21 +0.13 +12.04%
ABCLAbCellera Biologics9.76+0.42+4.50%-- 
Pre Market 9.2104 -0.5496 -5.63%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.